导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.73% | 3808/4773 |
| 近一周 | -3.56% | 4314/5462 |
| 近一月 | -6.45% | 3531/5421 |
| 近一季 | -0.13% | 763/5209 |
| 近半年 | -9.69% | 3537/4920 |
| 近一年 | -15.29% | 3685/4366 |
| 近两年 | 0.98% | 2878/2954 |
| 近三年 | -19.52% | 2150/2253 |
| 成立以来 | 8.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.15% 3058/4961 |
-12.40% 4401/5312 |
- - |
- - |
| 2025 | -3.94% 3357/4813 |
-4.62% 3209/3635 |
1.20% 2423/4076 |
2.00% 3845/4524 |
-2.42% 3146/4813 |
| 2024 | -5.13% 2259/3463 |
-3.93% 1582/2808 |
-6.37% 1927/3014 |
12.44% 2348/3129 |
-6.20% 2633/3463 |
| 2023 | 1.19% 366/2656 |
11.72% 326/2280 |
0.21% 333/2385 |
-5.58% 1340/2515 |
-4.27% 941/2655 |
| 2022 | -9.95% 192/2207 |
-3.61% 159/1919 |
-5.68% 1867/2016 |
-14.09% 1020/2113 |
15.30% 70/2208 |
| 2021 | 39.56% 35/1822 |
0.91% 272/1255 |
23.26% 117/1330 |
-9.91% 1199/1466 |
24.55% 4/1822 |
| 2020 | 20.84% 703/1250 |
-1.83% 243/1028 |
18.57% 331/1067 |
6.21% 866/1164 |
-2.26% 1118/1184 |
| 2019 | 5.78% 747/1092 |
19.93% 616/754 |
-8.73% 605/804 |
-6.14% 806/850 |
2.96% 849/918 |
| 2018 | -26.87% 406/834 |
- - |
- - |
- - |
-16.37% 634/691 |
| 2017 | 0.87% 464/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证中药ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |